BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37976123)

  • 1. The necroptosis signature and molecular mechanism of lung squamous cell carcinoma.
    Song GQ; Wu HM; Ji KJ; He TL; Duan YM; Zhang JW; Hu GQ
    Aging (Albany NY); 2023 Nov; 15(22):12907-12926. PubMed ID: 37976123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of an individualized prognostic signature of lung squamous cell carcinoma based on ferroptosis-related genes.
    Diao X; Guo C; Liu L; Wang G; Li S
    Thorac Cancer; 2021 Dec; 12(23):3236-3247. PubMed ID: 34672420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma.
    Wang X; Huang Z; Li L; Wang G; Dong L; Li Q; Yuan J; Li Y
    BMC Cancer; 2022 Aug; 22(1):866. PubMed ID: 35941578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma.
    Huang G; Zhang J; Gong L; Huang Y; Liu D
    BMC Cancer; 2021 May; 21(1):626. PubMed ID: 34044809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma.
    Miao TW; Yang DQ; Chen FY; Zhu Q; Chen X
    Biosci Rep; 2022 Aug; 42(8):. PubMed ID: 35866375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
    Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
    Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analyses of a CD8
    Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q
    BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.
    Xu F; Zhang H; Chen J; Lin L; Chen Y
    Int Immunopharmacol; 2020 Apr; 81():105932. PubMed ID: 31836430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific Lung Squamous Cell Carcinoma Prognosis-Subtype Distinctions Based on DNA Methylation Patterns.
    Huang G; Zhang J; Gong L; Liu D; Wang X; Chen Y; Guo S
    Med Sci Monit; 2021 Mar; 27():e929524. PubMed ID: 33661858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a DNA damage repair gene-related signature for lung squamous cell carcinoma prognosis.
    Jia B; Gong T; Sun B; Zhang Z; Zhong D; Wang C
    Thorac Cancer; 2022 Apr; 13(8):1143-1152. PubMed ID: 35293140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
    Pan J; Huang Z; Lin H; Cheng W; Lai J; Li J
    BMC Cancer; 2022 Nov; 22(1):1132. PubMed ID: 36333719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.
    Zhou H; Zhang H; Shi M; Wang J; Huang Z; Shi J
    Int Immunopharmacol; 2020 Nov; 88():106856. PubMed ID: 32777677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel 12-gene signature as independent prognostic model in stage IA and IB lung squamous cell carcinoma patients.
    Wang K; Li Y; Wang J; Chen R; Li J
    Clin Transl Oncol; 2021 Nov; 23(11):2368-2381. PubMed ID: 34028782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
    Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
    Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the Role and Regulation Mechanism of hsa-miR-147b in Lung Squamous Cell Carcinoma Based on The Cancer Genome Atlas Database.
    Ke D; Guo Q; Fan TY; Xiao X
    Cancer Biother Radiopharm; 2021 Apr; 36(3):280-291. PubMed ID: 33112657
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients.
    Liu X; Zhao D; Shan Y; Cui W; Xie Q; Jiang J; Peng W; Zhang C; Duan C
    Sci Rep; 2022 Dec; 12(1):20737. PubMed ID: 36456645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
    Zhang Y; Zhou J; Li H; Liu Y; Li J
    BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prognostic risk model based on DNA methylation levels of genes and lncRNAs in lung squamous cell carcinoma.
    Wang W; Xiang M; Liu H; Chu X; Sun Z; Feng L
    PeerJ; 2022; 10():e13057. PubMed ID: 35356464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.